Association of dynamic change in patient-reported pain with survival in metastatic castration-sensitive prostate cancer – exploratory analysis of the LATITUDE study

0
  • Kessel A, Kohli M, Swami U. Current management of metastatic castration-sensitive prostate cancer. Common Cancer Treat Res. 2021;28:100384.

    Google Scholar article

  • Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N. Metastatic castration-sensitive prostate cancer: optimizing patient selection and treatment. Am Soc Clin Oncol Educ B. 2018;38:363–71.

    Google Scholar article

  • Iacovelli R, Ciccarese C, Mosillo C, Bimbatti D, Fantinel E, Stefani L, et al. Comparison between prognostic classifications in de novo metastatic hormone-responsive prostate cancer. Target Oncol. 2018;13:649–55.

    Google Scholar article

  • Roy S, Morgan SC. Who dies of prostate cancer? An analysis of the database on surveillance, epidemiology and final results. Clin Oncol. 2019;31:630–6.

    CAS Google Scholar Article

  • James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to long-term first-line hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multi-arm, multi-stage, and randomized controlled trial to platform. Lancet. 2016;387:1163–77.

    CAS Google Scholar Article

  • Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide as standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121–31.

    CAS Google Scholar Article

  • James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–51.

    CAS Google Scholar Article

  • Fizazi K, Tran NP, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final analysis of overall survival from a randomized, double-blind, phase 3. Oncol lancet. 2019;20:686–700.

    CAS Google Scholar Article

  • Chi KN, Agarwal N, Bjartell A, Chung BH, Gomes AJPDS, Given R, et al. Apalutamide for metastatic castration-sensitive prostate cancer. N. Engl J Med. 2019;381:13–24.

    CAS Google Scholar Article

  • Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in hormone-responsive metastatic prostate cancer: analysis of long-term survival from the phase III randomized trial E3805. J Clin Oncol. 2018;36:1080–7.

    CAS Google Scholar Article

  • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

    CAS Google Scholar Article

  • Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Design and objectives of trials for castration-resistant prostate cancer: updated recommendations from the working group 3 on clinical trials in prostate cancer. J Clin Oncol. 2016;34:1402–18.

    Google Scholar article

  • Rucci N, Angelucci A. Prostate cancer and bone: elective affinities. Biomed Res Int. 2014 ; 2014. https://doi.org/10.1155/2014/167035.

  • Muralidharan A, Smith MT. Pathobiology and management of bone pain induced by prostate cancer: recent knowledge and future treatments. Inflammopharmacology. 2013;21:339–63.

    CAS Google Scholar Article

  • Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Anne Oncol. 2018;29:2200–7.

    CAS Google Scholar Article

  • Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, et al. Prognostic model predicting survival from metastatic castration-resistant prostate cancer in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013;105:1729–37.

    CAS Google Scholar Article

  • Cella D, Traina S, Li T, Johnson K, Ho KF, Molina A, et al. Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302. Anne Oncol. 2018;29:392–7.

    CAS Google Scholar Article

  • Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, et al. Pain predicts overall survival in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2008;26:2544–9.

    Google Scholar article

  • Iacovelli R, Ciccarese C, Caffo O, De Giorgi U, Tucci M, Mosillo C, et al. The prognostic value of pain in castration-sensitive prostate cancer. Prostate cancer Say. 2020;23:654–60.

    CAS Google Scholar Article

  • Halabi S, Li C, Luo S. Developing and validating clinical outcome risk assessment models in modern oncology. JCO Accurate Oncol. 2019: 1–12.

  • Jenkins DA, Sperrin M, Martin GP, ​​Peek N. Dynamic models for predicting health outcomes: current status and methodological challenges. Diagnosis Prog Res. 2018; 2: 1–9.

    Google Scholar article

  • Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, et al. Patient-reported outcomes after the combination of abiraterone acetate and prednisone with anti-androgen therapy in patients with newly diagnosed metastatic castration-naïve prostate cancer (LATITUDE): an international randomized trial phase 3. Lancet Oncol. 2018;19:194–206.

    CAS Google Scholar Article

  • Cleeland CS. The Brief Pain Inventory User’s Guide. www.mdanderson.org (accessed February 1, 2022).

  • Cook KF, Schalet BD, Kallen MA, Rutsohn JP, Cella D. Establishing a common metric for self-reported pain: relating BPI and SF-36 body pain subscale interference scores to the metric d PROMIS pain interference. Qual Life Res. 2015;24:2305–18.

    Google Scholar article

  • Rizopoulos D, Molenberghs G, Lesaffre EMEH. Dynamic predictions with time-dependent covariates in survival analysis using conjoint modeling and cueing. Biom J. 2017;59:1261–76.

    Google Scholar article

  • Rizopoulos, D. Joint models for longitudinal and temporal data: with applications in R. Boca Raton: Chapman and Hall/CRC. 2012.

  • Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient experience. Clin Cancer Res. 2006;12:6236s–6242s.

    Google Scholar article

  • N J. Bone metastases: management approaches. Semin Oncol. 2001;28:28–34.

  • McPherson CJ, Hadjistavropoulos T, Lobchuk MM, Kilgour KN. Cancer-related pain in older people receiving palliative care: patient and family caregiver perspectives on the pain experience. Pain Res Manag J Can Pain Soc. 2013;18:293.

    Google Scholar article

  • Cohen SR, Mount BM. Pain associated with a life-threatening disease: its perception and control are inextricably linked to quality of life. Pain Management 2000;5:971487.

    Google Scholar article

  • Molloy NH, Read DE, Gorman AM. Nerve growth factor in cancer cell death and survival. Cancer. 2011;3:510.

    Google Scholar article

  • Di Donato M., Cernera G, Migliaccio A, Castoria G. Nerve growth factor induces proliferation and aggressiveness of prostate cancer cells. Cancer. 2019;11. https://doi.org/10.3390/CANCERS11060784.

  • Chen WY, Wen YC, Lin SR, Yeh HL, Jiang KC, Chen WH, et al. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and resistance to castration. Common Biol. 2021;4:1–14. 2021 41

    Google Scholar article

  • Delanoy N, Robbrecht D, Fizazi K, Mercier F, Sartor O, De Wit R, et al. Pain progression at the start of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis: a post-hoc analysis by FIRSTANA. Anne Oncol. 2019;30:v335–v336.

    Google Scholar article

  • Armstrong AJ, Garrett-Mayer E, Yang YCO, Carducci MA, Tannock I, De Wit R, et al. Analysis of prostate-specific antigen and pain substitution in hormone-refractory metastatic prostate cancer. J Clin Oncol. 2007;25:3965–70.

    Google Scholar article

  • Dómine Gómez M, Díaz Fernández N, Cantos Sánchez de Ibargüen B, Zugazabeitia Olabarría L, Martínez Lozano J, Poza de Celis R, et al. Association of performance status and pain in the management of metastatic bone pain in the Spanish clinical setting. Adv Ther. 2016;34:136–47.

    Google Scholar article

  • Lin CC, Lai YL, Ward SE. Effect of cancer pain on performance status, mood states and level of hope in Taiwanese cancer patients. J Management of pain symptoms. 2003;25:29–37.

    Google Scholar article

  • Haus R, Janssen S, Schild SE, Rades D. The Eastern Cooperative Oncology Group performance score is associated with survival after radiotherapy of prostate cancer bone metastases. Live. 2020;34:679–82.

    Google Scholar article

  • Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME, et al. Initial management of advanced, recurrent, or metastatic uncastrated prostate cancer: ASCO guideline update. J Clin Oncol. 2021;39:1274–305.

    Google Scholar article

  • Fizazi K, Galceran JC, Foulon S, Roubaud G, McDermott R, Fléchon A, et al. A phase III trial with a 2 × 2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. Anne Oncol. 2021;32:S1299.

    Google Scholar article

  • Asghari A, Nicholas MK. Pain self-efficacy beliefs and pain behavior. A prospective study. Pain. 2001;94:85–100.

    Google Scholar article

  • Asghari A, Nicholas MK. Beliefs/coping strategies related to personality and pain: a prospective study. Clin J Pain. 2006;22:10–18.

    Google Scholar article

  • Czerw AI, Religioni U, Deptała A, Fronczak A. Pain, disease acceptance, adaptation to life with cancer, and coping strategies in patients with prostate cancer. Arch Med Sci. 2017;13:1459.

    Google Scholar article

  • Share.

    Comments are closed.